Log In
Print
BCIQ
Print
Print this Print this
 

Kappaproct (DIMS 0150)

  Manage Alerts
Collapse Summary General Information
Company InDex Pharmaceuticals AB
DescriptionDNA-based immunomodulatory sequence (DIMS) targeting toll-like receptor 9 (TLR9)
Molecular Target Toll-like receptor 9 (TLR9)
Mechanism of ActionToll-like receptor 9 (TLR9) agonist
Therapeutic ModalityNucleic acid: Linear DNA
Latest Stage of DevelopmentPhase III
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat chronic, active, treatment-refractory ulcerative colitis (UC); Treat severe ulcerative colitis (UC); Treat steroid-refractory inflammatory bowel disease (IBD)
Regulatory Designation

EU - Orphan Drug (Treat chronic, active, treatment-refractory ulcerative colitis (UC))

Partner

Almirall S.A.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today